TY - JOUR
T1 - Impact of comorbidity, Race, and marital status in men referred for prostate biopsy with PSA >20 ng/mL
T2 - A pilot study in high-risk patients
AU - Klaassen, Zachary
AU - Muller, Roberto
AU - Li, Qiang
AU - Tatem, Alexander J.
AU - King, Sherita A.
AU - Freedland, Stephen J.
AU - Madi, Rabii Hussein
AU - Terris, Martha K.
AU - Moses, Kelvin A.
N1 - Publisher Copyright:
© Copyright 2014 Zachary Klaassen et al.
PY - 2014
Y1 - 2014
N2 - Objective. To assess the impact of comorbidity, race, and marital status on overall survival (OS) among men presenting for prostate biopsy with PSA >20 ng/mL. Methods. Data were reviewed from 2000 to 2012 and 78 patients were included in the cohort. We analyzed predictors of OS using a Cox proportional hazardsmodel and the association between Charlson Comorbidity Index (CCI) score and PCA diagnosis or high-grade cancer using logistic regression and multinomial regression models, respectively. Results. The median age of patients was 62.5 (IQR 57-73) years.Median CCI was 3 (IQR 2-4), 69% of patients were African American men, 56% of patients were married, and 85% of patients had a positive biopsy. CCI (HR 1.52, 95% CI 1.19, 1.94), PSA (HR 1.62, 95% CI 1.09, 2.42), and Gleason sum (HR 2.04, 95% CI 1.17, 3.56) were associated with OS. CCI was associated with Gleason sum 7 (OR 4.06, 95% CI 1.04, 15.89) and Gleason sum 8-10 (OR 4.52, 95% CI 1.16, 17.54) PCA. Conclusions. CCI is an independent predictor of high-grade disease and worse OS among men with PCA. Race and marital status were not significantly associated with survival in this cohort. Patient comorbidity is an important component of determining the optimal approach to management of prostate cancer.
AB - Objective. To assess the impact of comorbidity, race, and marital status on overall survival (OS) among men presenting for prostate biopsy with PSA >20 ng/mL. Methods. Data were reviewed from 2000 to 2012 and 78 patients were included in the cohort. We analyzed predictors of OS using a Cox proportional hazardsmodel and the association between Charlson Comorbidity Index (CCI) score and PCA diagnosis or high-grade cancer using logistic regression and multinomial regression models, respectively. Results. The median age of patients was 62.5 (IQR 57-73) years.Median CCI was 3 (IQR 2-4), 69% of patients were African American men, 56% of patients were married, and 85% of patients had a positive biopsy. CCI (HR 1.52, 95% CI 1.19, 1.94), PSA (HR 1.62, 95% CI 1.09, 2.42), and Gleason sum (HR 2.04, 95% CI 1.17, 3.56) were associated with OS. CCI was associated with Gleason sum 7 (OR 4.06, 95% CI 1.04, 15.89) and Gleason sum 8-10 (OR 4.52, 95% CI 1.16, 17.54) PCA. Conclusions. CCI is an independent predictor of high-grade disease and worse OS among men with PCA. Race and marital status were not significantly associated with survival in this cohort. Patient comorbidity is an important component of determining the optimal approach to management of prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=85043551032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043551032&partnerID=8YFLogxK
U2 - 10.1155/2014/362814
DO - 10.1155/2014/362814
M3 - Article
AN - SCOPUS:85043551032
SN - 2090-5807
VL - 2014
JO - ISRN Urology
JF - ISRN Urology
M1 - 362814
ER -